Sfoglia per AUTORE
PARIS M
Collezione ASL Biella

  

Items : 3

Prospective, randomised, multicentre, open-label trial, designed to evaluate the best timing of closure of the temporary ileostomy (early versus late) in patients who underwent rectal cancer resection and with indication for adjuvant chemotherapy: the STOMAD (STOMa closure before or after ADjuvant therapy) randomised controlled trial. in BMJ open / BMJ Open. 2021 Feb 19;11(2):e044692. doi: 10.1136/bmjopen-2020-044692.

2021
ASL Torino 5
ASL Torino 4
ASL Asti
ASL Vercelli
ASL Torino 3
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
ASL Città di Torino
ASL Biella
AOU Città della Salute di Torino
ASL VCO
ASL Cuneo 2
ASL Cuneo 1
ASL Alessandria
AOU Novara

Mellano A; Battafarano F; De Rosa C; Colli F; Bellora P; Mazza L; Serventi A; Giaminardi E; Cravero F; Piscioneri D; Adamo V; Brunetti M; Rimonda R; Potente F; Carrera M; Panier Suffat L; Saccona F; Ponte E; Massucco P; Pipitone N; Birolo S; Calabrò M; Tomaselli F; Reddavid R; Santarelli M; Mistrangelo M; Mineccia M; Perotti S; Ciccone G; et alii...

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. in British journal of cancer / Br J Cancer. 2017 Jan;116(3):318-323. doi: 10.1038/bjc.2016.413. Epub 2017 Jan 12.

2017
ASL Biella
AO Cuneo

Cremolini C; Falcone A; Boni L; Tomcikova D; Paris M; Bonetti A; Martignetti A; Dargenio F; Miraglio E; Amoroso D; Banzi MC; Borelli B; Chiara S; Loupakis F; Masi G; Allegrini G; Barbara C; Salvatore L; Antonuzzo L; Marmorino F;

Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study in Journal of Clinical Oncology

2016
ASL Biella

Marmorino F; Cremolini C; Loupakis F; Barbara C; Dargenio F; Miraglio E; Masi G; Salvatore L; Marcucci L; Antonuzzo L; Chiara S; Banzi C; Schirripa M; Amoroso D; Bonetti A; Martignetti A; Paris M; Boni L; Tomcikova D; Falcone A;